Development of Vaccines for Ehrlichiosis

Thomas, Sunil

doi:10.1007/978-3-319-46859-4_9

Cited by 2 publications

(3 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have chosen B-cell epitopes that are close to N-terminus or C-terminus because these usually represent functional epitopes with higher activities [20] (Fig. 2).…”

Section: Identification Of B-cell Antigenic Epitopementioning

confidence: 99%

In Silico Identification of the B-Cell and T-Cell Epitopes of the Antigenic Proteins of Staphylococcus aureus for Potential Vaccines

Thomas

Doytchinova

2021

Vaccine Design

Self Cite

View full text Add to dashboard Cite

Staphylococcus aureus is a leading cause of community-acquired, healthcare-associated, and hospitalacquired infections. S. aureus bacteremia is a common and serious infection with significant morbidity and mortality in older patients. The rise of antibiotic-resistant strains of S. aureus has resulted in substantial loss and effective treatment in hospitalized patients. Thus, there is a need in the development of a vaccine that would provide protection against S. aureus. The antigens of our interest include proteins that are essential for bacterial attachment and colonization (ClfA and ClfB), dermonecrosis-driven toxin (Hla), antigens that are essential for abscess formation (EsxA and EsxB), and antigens that are essential for nutrient acquisition and resistance to phagocytes killing induced by reactive oxygen species (FhuD2 and MntC). Development of a structure-based vaccine based on the antigenic protein epitopes is a novel strategy to provide protection against S. aureus. Using bioinformatic tools, we have determined the B-cell and T-cell epitopes of the antigenic proteins of S. aureus. This chapter reports identification of B-cell and T-cell epitopes of the antigenic protein that could be used in the development of effective structure-based vaccines to protect against S. aureus.

show abstract

“…We have chosen B-cell epitopes that are close to N-terminus or C-terminus because these usually represent functional epitopes with higher activities [20] (Fig. 2).…”

Section: Identification Of B-cell Antigenic Epitopementioning

confidence: 99%

In Silico Identification of the B-Cell and T-Cell Epitopes of the Antigenic Proteins of Staphylococcus aureus for Potential Vaccines

Thomas

Doytchinova

2021

Vaccine Design

Self Cite

View full text Add to dashboard Cite

show abstract

“…E. chaffeensis and Ehrlichia canis cause canine ehrlichioses in dogs, whereas Ehrlichia ruminantium causes heartwater in cattle, sheep, and goats. As yet there are no commercially available vaccines to protect against these pathogens [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Ehrlichia are vector-borne diseases and transmitted by tick bites. The major factors associated with the emergence or re-emergence of vector-borne diseases include climate change, including global warming and shorter winter season that impact the development and activity of ticks, outdoor activities, global traveling, urbanization, changes in land use, deforestation, habitat fragmentation, natural environment encroachment, which together predispose to a higher contact among wildlife, humans, and domestic animals; the employment and easier access to molecular tools, favoring the diagnosis and identification of vector-borne agents; and the increase of awareness of tick-borne agents by veterinarians, physicians, scientists, and public health authorities [2,3].…”

Section: Introductionmentioning

confidence: 99%

Development of a SONIX Vaccine to Protect Against Ehrlichiosis

Thomas

2021

Vaccine Design

Self Cite

View full text Add to dashboard Cite

The obligately Gram-negative intracellular bacterium Ehrlichia that resides in mononuclear phagocytes is the etiologic agent of human monocytotropic ehrlichiosis (HME). HME is an emerging and often lifethreatening, tick-transmitted infectious disease in the USA. Currently, three different Ehrlichia species can cause ehrlichiosis in humans in the USA-Ehrlichia chaffeensis, Ehrlichia ewingii, and Ehrlichia muris subspecies eauclairensis. Ehrlichia also causes diseases in companion animals and domesticated ruminants. Ehrlichia are vector-borne diseases and transmitted by tick bites. As yet there are no commercially available vaccines to protect against these pathogens. Previously we developed structure-based vaccines and subunit vaccines to protect against ehrlichiosis in animal models. Though the vaccines are efficient in inducing protection, there is a delay in clearing the pathogens in challenge studies. In this chapter we demonstrate the development of a SONIX vaccine that is more potent than conventional vaccines. The vaccination strategy may be useful in Emergency Use Authorization (EUA) scenarios during public health emergencies.

show abstract

Development of Vaccines for Ehrlichiosis

Cited by 2 publications

References 64 publications

In Silico Identification of the B-Cell and T-Cell Epitopes of the Antigenic Proteins of Staphylococcus aureus for Potential Vaccines

In Silico Identification of the B-Cell and T-Cell Epitopes of the Antigenic Proteins of Staphylococcus aureus for Potential Vaccines

Development of a SONIX Vaccine to Protect Against Ehrlichiosis

Contact Info

Product

Resources

About